Who are Daprodustat tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Daprodustat small, Daprodustat (GSK1278863), Daprodustat large.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/daprodustat-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Daprodustat tablets — Competitive Intelligence Brief

Daprodustat tablets (Daprodustat tablets) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIF prolyl hydroxylase inhibitor. Area: Hematology / Nephrology.

phase 3 HIF prolyl hydroxylase inhibitor Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) Hematology / Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Daprodustat tablets (Daprodustat tablets) — GlaxoSmithKline. Daprodustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stimulates endogenous erythropoietin production to treat anemia.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Daprodustat tablets TARGET	Daprodustat tablets	GlaxoSmithKline	phase 3	HIF prolyl hydroxylase inhibitor	Hypoxia-inducible factor prolyl hydroxylase (HIF-PH)
Daprodustat small	Daprodustat small	GlaxoSmithKline	phase 3	HIF prolyl hydroxylase inhibitor	Prolyl hydroxylase domain-containing proteins (PHD)
Daprodustat (GSK1278863)	Daprodustat (GSK1278863)	GlaxoSmithKline	phase 3	HIF prolyl hydroxylase inhibitor	Prolyl hydroxylase domain-containing proteins (PHD)
Daprodustat large	Daprodustat large	GlaxoSmithKline	phase 3	HIF prolyl hydroxylase inhibitor	Prolyl hydroxylase (PHD)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIF prolyl hydroxylase inhibitor class)

GlaxoSmithKline · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Daprodustat tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/daprodustat-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab